Dissemination

Lin Chang, MD, AGAF spoke with Physician’s Weekly about the guideline and the overall topic of pharmacological management of IBS-C.

Physician’s Weekly recently spoke with Linda Girgis, MD, FAAFP, about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.

Physician’s Weekly recently spoke with William D. Chey, MD, FACG, AGAF, FACP, RFF, lead author of the phase 3 T3MPO-2 study—which assessed the efficacy of the NHE3 inhibitor tenapanor in treating patients with irritable bowel syndrome with constipation (IBS-C)—about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.

Physician’s Weekly recently spoke with Lin Chang, MD, AGAF, lead author of the 2022 AGA Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation (IBS-C).

Physician’s Weekly recently spoke with Brooks Cash, MD about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.

Physician’s Weekly recently spoke with Satish SC Rao, MD, PhD, FRCP, FACG, AGAF about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.

Physician’s Weekly spoke with a panel of experts in hepatology and oncology to discuss the role of two treatment guidelines in the management HCC.

Physician’s Weekly recently spoke with William D. Chey, MD, FACG, AGAF, FACP, RFF, the lead author...

Physician’s Weekly recently spoke with Brian E. Lacy, MD, PhD,  a board-certified...

Physician’s Weekly recently spoke with Gentry King, MD, a medical oncologist and published author...

Physician’s Weekly recently spoke with Robert Gish, MD, FAASLD, a self-identified hepatologist and...